Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Namodenoson

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    8-Year Survival with Cure for Liver Cancer with Namodenoson
    8-Year Survival with Cure for Liver Cancer with Namodenoson

    04 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/04/2991347/0/en/8-Years-Survival-with-Complete-Cure-for-a-Patient-with-Advanced-Liver-Cancer-Being-Treated-with-Can-Fite-s-Namodenoson-Drug.html

    GLOBENEWSWIRE
    04 Dec 2024
    Share Share
    Patient Improvement Reported With Namodenoson In Liver Cirrhosis
    Patient Improvement Reported With Namodenoson In Liver Cirrhosis

    01 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/01/2906564/0/en/Improvement-in-Patient-with-Decompensated-Liver-Cirrhosis-Upon-Treatment-with-Namodenoson.html

    GLOBENEWSWIRE
    01 Jul 2024
    Share Share
    Can-Fite demonstrates Namodenoson's anticancer and liver protective effects.
    Can-Fite demonstrates Namodenoson's anticancer and liver protective effects.

    24 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240624268136/en

    BUSINESSWIRE
    24 Jun 2024
    Share Share
    Can-Fite Gets IRB Approval For Pancreatic Cancer Study With Namodenoson
    Can-Fite Gets IRB Approval For Pancreatic Cancer Study With Namodenoson

    10 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240610723784/en

    BUSINESSWIRE
    10 Jun 2024
    Share Share
    Can-Fite: Namodenoson Long-Term CR in Advanced Liver Cancer Patient
    Can-Fite: Namodenoson Long-Term CR in Advanced Liver Cancer Patient

    25 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240425661063/en

    BUSINESSWIRE
    25 Apr 2024
    Share Share
    Can-Fite: Namodenoson Promising For Liver Cancer, MASH
    Can-Fite: Namodenoson Promising For Liver Cancer, MASH

    15 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240415044511/en

    BUSINESSWIRE
    15 Apr 2024
    Share Share